Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.025 | 0.7 |
mRNA | Dasatinib | FIMM | pan-cancer | AAC | -0.065 | 0.7 |
mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |